The effect of henagliflozein proline in patients with IgA nephropathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079954

Enrollment

Unknown

Registered

2024-01-17

Start date

2024-01-20

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

control group:ACEI/ARB drug

henagliflozein proline group:ACEI/ARB+ henagliflozein proline drug

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age =18 years old; eGFR=25 and =75 ml/min/1.73m²; Urinary protein to creatinine ratio (UPCR) =200 mg/g and =5000 mg/g; 100 patients with IgA nephropathy were treated with stable, maximally tolerated doses of ACEI or ARB for at least 4 weeks

Exclusion criteria

Exclusion criteria: With type 1 or type 2 diabetes, known hypersensitivity to proline hemaglizin, myocardial infarction or stroke in the last 6 months, acute phase of urinary tract infection, significant liver function impairment (glutamic-pyrugal transaminase exceeding 3 times the upper limit of normal), IgA nephropathy treated with steroids in the previous year, known renal artery stenosis, severe nephrotic syndrome (serum albumin less than 2g/dl), severe infection, malignant tumor, pregnancy breastfeeding.

Design outcomes

Primary

Measure	Time frame
24 hour urine protein;UPCR;	—

Secondary

Measure	Time frame
kidney funtion;liver funtion;blood pressure;weight;	—

Countries

China

Contacts

Public ContactJunxia Wu

the Second Affiliated Hospital Zhejiang University School of Medicine

wujunxia@zju.edu.cn+86 158 2550 9402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026